<table id="t6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6	Established and Other Potentially Significant<footnote>This table is not all inclusive.</footnote> Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="55%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule" valign="middle">Concomitant Drug Class: Drug Name</th>
<th align="center" stylecode="Rrule" valign="middle"> Potential Effect <footnote>↑ = Increase, ↓ = Decrease, ↔ = No change</footnote>
</th>
<th align="center" stylecode="Rrule" valign="middle">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td align="left" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Antiretroviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">efavirenz</td>
<td stylecode="Rrule">↓ cobicistat<br/>↓ darunavir<br/>↓ atazanavir</td>
<td stylecode="Rrule">
<content stylecode="bold">TYBOST coadministered with darunavir:</content>
<br/>Coadministration of darunavir and TYBOST with efavirenz is not recommended because it may result in the loss of therapeutic effect and development of resistance to darunavir.<br/>
<br/>
<content stylecode="bold">TYBOST coadministered with atazanavir:</content>
<br/>
<br/>
<content stylecode="bold italics">In treatment-naïve patients:</content> Atazanavir 400 mg with TYBOST150 mg should be coadministered once daily as a single dose with food, and efavirenz 600 mg should be administered once daily on an empty stomach, preferably at bedtime.<br/>
<br/>
<content stylecode="bold italics">In treatment-experienced patients: </content>Coadministration of atazanavir and TYBOST with efavirenz in treatment-experienced patients is not recommended because it may result in the loss of therapeutic effect and development of resistance to atazanavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">etravirine</td>
<td stylecode="Rrule">↓ cobicistat<br/>darunavir: effect unknown 											 											<br/>↓ atazanavir</td>
<td stylecode="Rrule">Coadministration with etravirine is not recommended because it may result in the loss of therapeutic effect and development of resistance to atazanavir or darunavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">nevirapine</td>
<td stylecode="Rrule">↓ cobicistat<br/>darunavir: effect unknown</td>
<td stylecode="Rrule">TYBOST coadministration with nevirapine and darunavir is not recommended because it may result in the loss of therapeutic effect and development of resistance to darunavir.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Antiretroviral Agents: CCR5 Antagonists</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">maraviroc</td>
<td stylecode="Rrule">↑ maraviroc</td>
<td stylecode="Rrule">Maraviroc is a substrate of CYP3A. When coadministering with maraviroc, patients should receive maraviroc 150 mg twice daily.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents:</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antacids:</content>
<br/>e.g., aluminum and magnesium hydroxide<br/>
<content stylecode="italics">(please also see H<sub>2</sub>-<linkhtml href="#receptor_antagonists">receptor antagonists</linkhtml> and <linkhtml href="#proton_pump_inhibitors">proton pump inhibitors</linkhtml> below)</content>
</td>
<td stylecode="Rrule">↓ atazanavir</td>
<td stylecode="Rrule">
<content stylecode="bold">TYBOST coadministered with atazanavir:</content>
<br/>With concomitant use, administer a minimum of 2 hours apart. 											</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antiarrhythmics:</content>
<br/>e.g.,<br/>amiodarone<br/>disopyramide<br/>flecainide<br/>mexiletine<br/>propafenone<br/>quinidine</td>
<td stylecode="Rrule">↑ antiarrhythmics</td>
<td stylecode="Rrule">Clinical monitoring is recommended upon coadministration with antiarrhythmics.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">digoxin</td>
<td stylecode="Rrule">↑ digoxin</td>
<td stylecode="Rrule">When coadministering with digoxin, titrate the digoxin dose and monitor digoxin concentrations.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antibacterials </content>(macrolide or ketolide antibiotics):<br/>clarithromycin<br/>erythromycin<br/>telithromycin</td>
<td stylecode="Rrule">↑ clarithromycin<br/>↑ erythromycin<br/>↑ telithromycin<br/>↑ cobicistat<br/>↑ atazanavir<br/>↑ darunavir</td>
<td stylecode="Rrule">Consider alternative antibiotics with concomitant use of TYBOST coadministered with atazanavir or darunavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticancer Agents:</content>
<br/>dasatinib<br/>nilotinib<br/>vinblastine<br/>vincristine</td>
<td stylecode="Rrule">↑ anticancer agents</td>
<td stylecode="Rrule">A decrease in the dosage or an adjustment of the dosing interval of dasatinib or nilotinib may be necessary upon coadministration with TYBOST. Consult the dasatinib and nilotinib prescribing information for dosing instructions.<br/>For vincristine and vinblastine, monitor for hematologic or gastrointestinal side effects.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticoagulants:</content>
<br/>warfarin<br/>
</td>
<td stylecode="Rrule">warfarin: effect unknown<br/>
</td>
<td stylecode="Rrule">Monitor the international normalized ratio (INR) when coadministering with warfarin. 											</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<br/>rivaroxaban</td>
<td stylecode="Rrule">
<br/>↑ rivaroxaban</td>
<td stylecode="Rrule">
<br/>Avoid coadministration with rivaroxaban which may result in increased exposure of rivaroxaban and increased risk of bleeding.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants: </content>
<br/>Anticonvulsants that induce CYP3A (e.g., carbamazepine, oxcarbazepine, phenytoin, phenobarbital)</td>
<td stylecode="Rrule">↓ cobicistat<br/>↓ atazanavir<br/>darunavir: effect unknown</td>
<td stylecode="Rrule">Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. If coadministration is necessary, monitor for lack or loss of virologic response.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<br/>phenobarbital <br/>phenytoin</td>
<td stylecode="Rrule">
<br/>phenobarbital:<br/> effect unknown<br/>phenytoin: effect unknown</td>
<td stylecode="Rrule">
<br/>Monitor phenobarbital or phenytoin concentrations.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule Botrule">
<br/>Anticonvulsants that are metabolized by CYP3A (e.g., clonazepam, carbamazepine)</td>
<td stylecode="Rrule Botrule">
<br/>↑ clonazepam<br/>↑ carbamazepine</td>
<td stylecode="Rrule Botrule">
<br/>Clinical monitoring of anticonvulsants is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antidepressants:</content>
<br/>Selective Serotonin Reuptake Inhibitors (SSRIs)<br/>e.g.,<br/>paroxetine<br/>
<br/>Tricyclic Antidepressants (TCAs)<br/>e.g.,<br/>amitriptyline<br/>desipramine<br/>imipramine<br/>nortriptyline<br/>
<br/>Other antidepressants:<br/>trazodone</td>
<td stylecode="Rrule">SSRIs: effects unknown<br/>↑ TCAs<br/>↑ trazodone<br/>
</td>
<td stylecode="Rrule">When coadministering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antifungals:</content>
<br/>itraconazole<br/>ketoconazole<br/>voriconazole<br/>
</td>
<td stylecode="Rrule">↑ itraconazole<br/>↑ ketoconazole<br/>Voriconazole: effects unknown<br/>↑ cobicistat<br/>↑ atazanavir<br/>↑ darunavir<br/>
</td>
<td stylecode="Rrule">Specific dosing recommendations are not available for coadministration with itraconazole or ketoconazole. <br/>
<br/>Coadministration with voriconazole is not recommended unless the benefit/risk assessment justifies the use of voriconazole.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anti-gout:</content>
<br/>colchicine</td>
<td stylecode="Rrule">↑ colchicine<br/>
</td>
<td stylecode="Rrule">Coadministration with colchicine in patients with renal or hepatic impairment is not recommended.<br/>
<content stylecode="underline">Treatment of gout flares - coadministration of colchicine:</content>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.<br/>
<content stylecode="underline">Prophylaxis of gout flares - coadministration of colchicine:</content>
<br/>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<content stylecode="underline">Treatment of familial Mediterranean fever - coadministration of colchicine:</content>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterial:</content>
<br/>rifabutin<br/>
</td>
<td stylecode="Rrule">↑ rifabutin<br/>cobicistat: effects unknown<br/>darunavir: effects unknown<br/>atazanavir: effects unknown<br/>
</td>
<td stylecode="Rrule">The recommended dosage regimen for rifabutin is 150 mg every other day. Monitor for rifabutin associated adverse reactions including neutropenia and uveitis.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Beta-Blockers:</content>
<br/>e.g.,<br/>metoprolol<br/>carvedilol<br/>timolol<br/>
</td>
<td stylecode="Rrule">↑ beta-blockers</td>
<td stylecode="Rrule">Clinical monitoring is recommended for coadministration with beta-blockers that are metabolized by CYP2D6.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium Channel Blockers:</content>
<br/>e.g.,<br/>amlodipine<br/>diltiazem<br/>felodipine<br/>nifedipine<br/>verapamil</td>
<td stylecode="Rrule">↑ calcium channel blockers</td>
<td stylecode="Rrule">Clinical monitoring is recommended for coadministration with calcium channel blockers metabolized by CYP3A.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroids (systemic):</content>
<br/>e.g.,<br/>dexamethasone<br/>
</td>
<td stylecode="Rrule">↓ cobicistat<br/>↓darunavir<br/>↓ atazanavir<br/>↑corticosteroids<br/>
</td>
<td stylecode="Rrule">Coadministration with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to atazanavir or darunavir. 												<br/>Consider alternative corticosteroids.<br/>Coadministration with corticosteroids that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. Consider the potential benefit of treatment versus the risk of systemic corticosteroid effects.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled/Nasal Corticosteroids:</content>
<br/>e.g.,<br/>fluticasone<br/>budesonide</td>
<td stylecode="Rrule">↑ corticosteroids</td>
<td stylecode="Rrule">Coadministration with inhaled or nasal fluticasone or other corticosteroids that are metabolized by CYP3A may result in reduced serum cortisol concentrations. Alternative corticosteroids should be considered, particularly for long term use.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Endothelin Receptor Antagonists:</content>
<br/>bosentan</td>
<td stylecode="Rrule">↑ bosentan<br/>↓ cobicistat<br/>↓ darunavir<br/>↓ atazanavir<br/>
</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of bosentan in patients taking TYBOST coadministered with atazanavir or darunavir</content>
<content stylecode="underline">:</content>
<br/>In patients who have been receiving TYBOST coadministered with atazanavir or darunavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<content stylecode="underline">Initiation of TYBOST coadministered with atazanavir or darunavir </content>
<content stylecode="underline">in patients taking bosentan:</content>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of TYBOST coadministered with atazanavir or darunavir. After at least 10 days following the initiation of TYBOST combined with atazanavir or darunavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<content stylecode="underline">Switching from ritonavir to TYBOST coadministered with atazanavir or darunavir:</content>
<br/>Maintain bosentan dose.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content id="receptor_antagonists" stylecode="bold">H<sub>2</sub>-Receptor Antagonists:</content>
<br/>e.g.,<br/>famotidine</td>
<td stylecode="Rrule">↓ atazanavir<br/>
</td>
<td stylecode="Rrule">
<content stylecode="bold">TYBOST coadministered with atazanavir:</content>
<br/>Administer atazanavir/TYBOST either at the same time or a minimum of 10 hours after administering H<sub>2</sub>-receptor antagonists. The dose of the H<sub>2</sub>-receptor antagonist should not exceed a dose comparable to famotidine 40 mg twice daily in treatment-naïve patients or 20 mg twice daily in treatment-experienced patients.<br/>
<br/>
<content stylecode="bold">TYBOST coadministered with atazanavir and tenofovir DF:</content>
<br/>Treatment-experienced patients: The recommended once daily dosage regimen is TYBOST 150 mg coadministered with atazanavir 400 mg with concomitant use of H<sub>2</sub>-receptor antagonists and tenofovir. 											</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HCV Protease Inhibitors:</content>
<br/>boceprevir<br/>telaprevir<br/>
<br/>
<br/>
<br/>simeprevir 											</td>
<td stylecode="Rrule Toprule">darunavir: effects unknown<br/>atazanavir: effects unknown<br/>
<br/>boceprevir: effects unknown<br/>telaprevir: effects unknown<br/>
<br/>↑ simeprevir 											</td>
<td stylecode="Rrule Toprule">No drug interaction data are available. Coadministration with boceprevir, simeprevir, or telaprevir is not recommended. 											</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA Reductase Inhibitors: </content>
<br/>e.g.,<br/>atorvastatin<br/>rosuvastatin<br/>
</td>
<td stylecode="Rrule">↑ HMG-CoA reductase inhibitors<br/>
</td>
<td stylecode="Rrule">For HMG-CoA reductase inhibitors that are not contraindicated with TYBOST, start with the lowest recommended dose and titrate while monitoring for safety <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml>].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Hormonal Contraceptives:</content>
<br/>progestin/estrogen</td>
<td stylecode="Rrule">progestin: effects unknown<br/>estrogen: effects unknown</td>
<td stylecode="Rrule">No data are available to make recommendations on the coadministration of TYBOST and atazanavir or darunavir with oral or other hormonal contraceptives. Additional or alternative (non-hormonal) forms of contraception should be considered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immuno-suppressants:</content>
<br/>cyclosporine<br/>everolimus<br/>sirolimus<br/>tacrolimus</td>
<td stylecode="Rrule">↑ immuno-suppressants</td>
<td stylecode="Rrule">These immunosuppressant agents are metabolized by CYP3A. Therapeutic drug monitoring is recommended if coadministered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled Beta Agonist:</content>
<br/>salmeterol</td>
<td stylecode="Rrule">↑ salmeterol</td>
<td stylecode="Rrule">Coadministration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.  </td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic analgesics<br/>For treatment of opioid dependence:</content>
<br/>buprenorphine<br/>buprenorphine/naloxone<br/>methadone<br/>
</td>
<td stylecode="Rrule">buprenorphine or buprenorphine/naloxone: effects unknown<br/>methadone: effects unknown<br/>
</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of buprenorphine, buprenorphine/naloxone, or methadone in patients taking TYBOST coadministered with atazanavir or darunavir:</content>
<br/>Carefully titrate the dose of buprenorphine, buprenorphine/naloxone, or methadone to the desired effect; use the lowest feasible initial or maintenance dose.<br/>
<content stylecode="underline">
<br/>Initiation of TYBOST coadministered with atazanavir or darunavir in patients taking buprenorphine, buprenorphine/naloxone, or methadone:</content>
<br/>A dose adjustment for buprenorphine, buprenorphine/naloxone, or methadone may be needed. Monitor clinical signs and symptoms. 											</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<br/>fentanyl<br/>
</td>
<td stylecode="Rrule">
<br/>↑ fentanyl<br/>
</td>
<td stylecode="Rrule">
<br/>Careful monitoring of therapeutic and adverse effects of fentanyl (including potentially fatal respiratory depression) is recommended with coadministration.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<br/>tramadol</td>
<td stylecode="Rrule">
<br/>↑ tramadol</td>
<td stylecode="Rrule">
<br/>A dose decrease may be needed for tramadol with concomitant use. 											</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Neuroleptics: </content>
<br/>e.g.,<br/>perphenazine<br/>risperidone<br/>thioridazine<br/>
</td>
<td stylecode="Rrule">↑ neuroleptics</td>
<td stylecode="Rrule">A decrease in the dose of neuroleptics that are CYP3A or CYP2D6 metabolized may be needed upon coadministration.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Phosphodiesterase-5 (PDE-5) Inhibitors: </content>
<br/>avanafil<br/>sildenafil<br/>tadalafil<br/>vardenafil</td>
<td stylecode="Rrule">↑ PDE-5 inhibitors</td>
<td stylecode="Rrule">Coadministration with avanafil is not recommended because a safe and effective avanafil dosage regimen has not been established.<br/>
<br/>Coadministration with TYBOST may result in an increase in PDE-5 inhibitor associated adverse events, including hypotension, syncope, visual disturbances, and priapism.<br/>
<br/>
<content stylecode="underline">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</content>
<list listtype="unordered">
<item>
<caption>•</caption>Use of sildenafil is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH)  <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml>].</content>
</item>
<item>
<caption>•</caption>The following dose adjustments are recommended for tadalafil concomitant use:<br/>
<content stylecode="italics">Initiation of tadalafil in patients taking TYBOST coadministered with atazanavir or darunavir:</content>
<br/>
<list listtype="unordered">
<item>
<caption> </caption>In patients taking TYBOST coadministered with atazanavir or darunavir for at least 1 week, start tadalafil at 20 mg once daily. Increase tadalafil dose to 40 mg once daily based upon individual tolerability.</item>
</list>
</item>
<item>
<caption> </caption>
<content stylecode="italics">Initiation of TYBOST coadministered with atazanavir or darunavir in patients taking tadalafil:</content>
<list listtype="unordered">
<item>
<caption> </caption>Avoid use of tadalafil during the initiation of TYBOST coadministered with atazanavir or darunavir.</item>
<item>
<caption> </caption>Stop tadalafil at least 24 hours prior to starting TYBOST coadministered with atazanavir or darunavir. After at least one week following initiation of TYBOST coadministered with atazanavir or darunavir, resume tadalafil at 20 mg once daily. Increase tadalafil dose to 40 mg once daily based upon individual tolerability.</item>
</list>
</item>
<item>
<caption> </caption>
<content stylecode="italics">Patients switching from ritonavir to TYBOST coadministered with atazanavir or darunavir:</content>
<list listtype="unordered">
<item>
<caption> </caption>Maintain tadalafil dose.</item>
</list>
</item>
</list>
<content stylecode="underline">Use of PDE-5 inhibitors for erectile dysfunction:</content>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours, or tadalafil at a single dose not exceeding 10 mg in 72 hours can be used with increased monitoring for PDE-5 inhibitor associated adverse events.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content id="proton_pump_inhibitors" stylecode="bold">Proton-pump Inhibitors (PPIs)</content>
<br/>e.g., omeprazole</td>
<td stylecode="Rrule">↓ atazanavir</td>
<td stylecode="Rrule">
<content stylecode="bold">TYBOST coadministered with atazanavir:</content>
<br/>In treatment-naïve patients, administer TYBOST with atazanavir a minimum of 12 hours after administering PPIs. The dose of the PPI should not exceed a dose comparable to omeprazole 20 mg daily.<br/>
<br/>In treatment-experienced patients, coadministration with PPIs, with or without tenofovir, is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Sedative/hypnotics:</content>
<br/>e.g.,<br/>buspirone<br/>diazepam<br/>parenterally-administered midazolam</td>
<td stylecode="Rrule">↑ sedatives/hypnotics<br/>
</td>
<td stylecode="Rrule">Coadministration with parenteral midazolam may increase plasma concentrations of midazolam. Coadministration should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosing reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.<br/>
<br/>Concomitant use with oral midazolam is contraindicated <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml>]</content>.<br/>
<br/>With other sedatives/hypnotics that are CYP3A metabolized, dose reduction may be necessary and clinical monitoring is recommended.</td>
</tr>
</tbody>
</table>